Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Clinical trial NCT07709585 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07709585
Sponsor: Guangzhou University of Traditional Chinese Medicine
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Non-small Cell Lung Cancer (NSCLC)EGFR Exon 19 Deletion Mutation EGFR Exon 21 Mutation EGFR Exon 21 L858R Mutation

Start date: 2026-07-05
Primary completion: 2030-07-31
Enrollment: 124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.